Related Experiment Video
Updated: Jan 30, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Insights
Intensive hypolipidemic therapy, combining statins with ezetimibe, fibrates, or PCSK9 inhibitors, is crucial for managing dyslipidemia and reducing cardiovascular disease risk. Achieving lipid targets often requires combination drug approaches.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Dyslipidemia is a primary risk factor for atherosclerosis.
- Achieving target blood lipid levels frequently necessitates intensive hypolipidemic therapy.
Purpose of the Study:
- To review the effectiveness of various hypolipidemic drug combinations.
- To assess the impact of these combinations on lipid profiles and cardiovascular disease incidence.
Main Methods:
- Literature review of studies on hypolipidemic drug combinations.
- Analysis of data on lipid-lowering effects and cardiovascular outcomes.
Main Results:
- Highest tolerated statin dose is foundational.
- Ezetimibe and fibrates are considered for add-on therapy.
- PCSK9 inhibitors are an option for high-risk patients.
Conclusions:
- Combination therapy is often required to meet lipid targets in dyslipidemia.
- Strategic use of statins, ezetimibe, fibrates, and PCSK9 inhibitors is key for cardiovascular risk reduction.
Abstract:
Dyslipidemia belongs to the main risk factors for atherosclerosis. To achieve current blood lipid targets, it is often necessary to use intensive hypolipidemic therapy including a combination of individual hypolipidemic drugs. In terms of cardiovascular risk reduction, it is important that the patient is treated with the highest tolerated dose of statin. In the next step, we decide to co-administer ezetimibe and/or fibrate, and for high-risk patients an additional treatment with proprotein convertase subtilisin kexin 9 inhibitors should be considered. The manuscript provides an overview of the individual combinations effectiveness to influence lipid spectrum and the incidence of cardiovascular diseases. Key words: cardiovascular disease - dyslipidemia - ezetimibe - fibrates - PCSK9 inhibitors - statins.
More Related Videos
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Vapor Pressure Lowering
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
What are Lipids?
What are Lipids?
Non-Polar and Hydrophobic Characteristics of Lipids
Lipids are a structurally and functionally diverse group of hydrocarbons—compounds consisting of carbon and hydrogen atoms. The carbon-carbon and...
Lipid Digestion

